RET fusion-positive non-small cell lung cancer
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
Indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.